United States Rystiggo Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united states rystiggo drug market size is expected to increase from USD 310.96 million in 2025 to USD 369.37 million in 2026 and reach USD 538.97 million by 2031, growing at a CAGR of 7.85% over 2026-2031. This report is Segmented by Antibody Type (AChR-Positive, MuSK-Positive), Dosage Strength (280 Mg/2 ML, 420 Mg/3 ML, 560 Mg/4 ML, 840 Mg/6 ML), Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, Other Distribution Channels), End User (Hospitals, Specialty Neurology Clinics, Home Care Settings). The Market Forecasts are Provided in Terms of Value (USD).

United States Rystiggo Drug Market Trends and Insights

Rapid Uptake of FcRn-Targeted Biologics in Specialty Neurology

The FcRn inhibitor class changed how neurologists approached generalized myasthenia gravis, because treatment focus moved away from broad immunosuppression toward targeted reduction of pathogenic autoantibodies in the United States Rystiggo drug market. Rozanolixizumab works by blocking FcRn recycling and lowering circulating IgG, including pathogenic AChR and MuSK autoantibodies, which separates it mechanistically from acetylcholinesterase inhibitors and non-specific steroids. Published systematic review and meta-analysis evidence across 8 randomized controlled trials and 873 patients showed that FcRn inhibitors improved MG-ADL, QMG, and MGC scores versus placebo, which supported growing class confidence among neurologists. That prior class familiarity mattered because physicians who had already used FcRn therapy in practice were more prepared to adopt Rystiggo for patients with incomplete response to intravenous alternatives in the United States Rystiggo drug market. UCB also presented long-term evidence from the MG0004 and MG0007 open-label extension studies in 2025, which reinforced tolerability and retreatment efficacy across repeated symptom-driven cycles. Those data supported payer renewals and physician confidence, and they helped the United States Rystiggo drug market move closer to a chronic management model instead of a one-time rescue pattern.

Broad AChR and MuSK Label Expands Treatable Population

Rystiggo’s dual approval for both AChR-positive and MuSK-positive disease remains commercially important because it reaches a broader treated pool than agents limited to AChR-positive labeling. MuSK-positive patients accounted for only a small portion of all myasthenia gravis cases, but they represented a larger share of refractory and treatment-resistant disease, which made this label breadth more meaningful than headline prevalence numbers suggested. U.S. prevalence estimates ranged from nearly 116,000 diagnosed patients to 135,000 when broader claims coverage was considered, and that created a defined addressable pool for targeted therapy in the United States Rystiggo drug market. Within that group, MuSK-positive disease represented 6% to 8% of cases and nearly 40% of AChR-seronegative patients, which kept Rystiggo relevant for a niche that historically relied on off-label management. The April 2025 approval of IMAAVY narrowed Rystiggo’s label advantage because Johnson & Johnson entered the same AChR-positive and MuSK-positive space with an intravenous FcRn blocker. Even so, Rystiggo preserved a practical convenience edge through its subcutaneous route and established access setup, which kept the United States Rystiggo drug market well positioned as site-of-care economics became more important to payers.

High Annual Therapy Cost and Prior Authorization Friction

Rystiggo’s U.S. list price was USD 3,155.37 per mL, and a single 6-week treatment cycle for heavier patients could reach USD 75,000 to USD 90,000 at the vial level. That cost places the therapy among the highest-priced specialty neurology biologics per episode of care, which naturally tightens payer scrutiny in the United States Rystiggo drug market. Major commercial payers required prior authorization and often asked for confirmed MGFA Class II to IVa disease plus prior exposure to conventional immunosuppressive therapy before approval. Initial approvals commonly ran for 6 months and renewals then required additional response documentation, which turned access into a repeated administrative process rather than a one-time review. That matters because Rystiggo uses symptom-driven treatment cycles, and even responding patients can face delays if payer documentation thresholds are not met consistently across renewals. UCB’s support structure eases part of that burden, but the cost and authorization barrier remains one of the clearest limits on the near-term growth pace of the United States Rystiggo drug market.

Other drivers and restraints analyzed in the detailed report include:

• Self-Administered or Clinic-Light Dosing Supports Adherence and Site-of-Care Shift
• Orphan Neurology Reimbursement Pathways Support Early Access
• Safety Monitoring Burden, Infection Risk, and Vaccine Restrictions

Segment Analysis

AChR-positive patients held 68.31% of the United States Rystiggo drug market share in 2025, which kept them as the core treated population inside the antibody-type split FDA.GOV. This lead reflected the simple fact that AChR antibodies are present in the majority of adult generalized myasthenia gravis cases, so neurologists naturally focused first on that broader diagnosed base. In practice, these patients formed the main prescribing target when physicians moved beyond pyridostigmine, corticosteroids, or non-steroidal immunosuppressants and stepped into FcRn therapy. The pivotal MycarinG study supported that use pattern because it showed clinically meaningful improvement in MG-ADL and QMG scores by Day 43 across the antibody groups studied. That broad efficacy base anchored the antibody segment structure of the United States Rystiggo drug market, because it gave prescribers confidence that the drug could serve more than one immunologic profile.

MuSK-positive patients are projected to grow at a 9.38% CAGR through 2031, making them the fastest-growing antibody sub-segment in the United States Rystiggo drug market size outlook. MuSK antibodies were found in nearly 6% of all myasthenia gravis cases and in nearly 40% of AChR-seronegative patients, which made diagnostic improvement especially important for this subpopulation. These patients often showed more severe bulbar and facial involvement and had weaker response to cholinesterase inhibitors, so clinical demand for a targeted approved option remained high. Before 2025, the lack of approved alternatives gave Rystiggo a very favorable position in this niche, and that early foothold still matters even after the arrival of IMAAVY. The growth outlook therefore reflects both a real unmet-need base and rising physician attention to antibody subtype testing, which should keep MuSK treatment volumes expanding faster than the broader United States Rystiggo drug market.

The 560 mg/4 mL vial held 39.24% of the dosage-strength segment in 2025, which made it the leading presentation in the United States Rystiggo drug market. That position fits the weight-tiered dosing structure, because patients treated at nearly 7 mg/kg in the 70 kg to 80 kg range often align naturally with this configuration. Rystiggo is supplied in 280 mg/2 mL, 420 mg/3 mL, 560 mg/4 mL, and 840 mg/6 mL single-dose vials, and that portfolio lets pharmacies match dosing more closely to body weight. The 280 mg/2 mL and 420 mg/3 mL formats continue to serve lighter patients and combination-fill needs, but they do not appear to sit at the center of routine dispensing volume. The leading share of the 560 mg/4 mL vial therefore reflects the modal treated patient profile rather than a simple packaging preference inside the United States Rystiggo drug market.

The 840 mg/6 mL vial is forecast to grow at a 9.52% CAGR through 2031, which makes it the fastest-expanding strength format. This pattern points to broader use among heavier patients and among patients maintained on the 10 mg/kg tier across repeated treatment cycles. Open-label extension work from MG0007 and MG0004, which UCB highlighted in 2025, supported continued use across multiple symptom-driven cycles in patients with more persistent disease burden. The 840 mg/6 mL presentation also offers operational advantages because a single-unit fill can reduce dispensing complexity for specialty pharmacies and hospital pharmacies handling higher-weight patients. That shift does not change the current leadership of the 560 mg/4 mL vial, but it shows that treated-patient mix in the United States Rystiggo drug market is broadening in a way that favors stronger single-vial presentations.

Complete Report Scope:

• By Antibody Type
  • AChR-Positive
  • MuSK-Positive
• By Dosage Strength
  • 280 mg / 2 mL
  • 420 mg / 3 mL
  • 560 mg / 4 mL
  • 840 mg / 6 mL
• By Distribution Channel
  • Specialty Pharmacies
  • Hospital Pharmacies
  • Other Distribution Channels
• By End User
  • Hospitals
  • Specialty Neurology Clinics
  • Home Care Settings

List of Companies Covered in this Report:

• UCB

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support